Annefleur Machteld de Bruijn

Annefleur Machteld de Bruijn

Auto-generated profile, based on publicly available information

Annefleur Machteld de Bruijn

Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2019 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
TBThierry Van Den Bosch
Thierry Van Den Bosch
ABAnnefleur M. de Bruijn
Annefleur M. de Bruijn
RLRobert A. de Leeuw
Robert A. de Leeuw
MDMargit Dueholm
Margit Dueholm
CECaterina Exacoustos
Caterina Exacoustos
JHJudith A.F. Huirne
Judith A.F. Huirne
Objective To develop a uniform classification and standardized reporting system of ultrasound findings of adenomyosis using the Morphological Uterus Sonographic Assessment (MUSA) criteria. Method The opinion presented in this manuscript was built based on a thorough discussion among all authors, including a Delphi procedure. Selected images and videos of typical cases of the different morphological variations of adenomyosis were used in the debates. Results A classification and reporting system of different types of adenomyosis based on ultrasound was agreed upon including (1) identification of adenomyosis based on MUSA criteria, (2) disease location (anterior, posterior, left lateral, right lateral, fundal), (3) classification of the lesions as focal or diffuse, (4) presence or absence of intralesional cysts, (5) myometrial layer involvement (junctional zone, myometrium, serosal involvement), (6) disease extent (< 25%, 25‐50%, > 50% of uterine volume affected by adenomyosis) and (7) lesion size. Conclusions We proposes a uniform classification and reporting system of different types of adenomyosis based on ultrasound. The clinical relevance of this approach needs to be evaluated in further studies. This article is protected by copyright. All rights reserved

1 December 2016 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
ABAnnefleur M. de Bruijn
Annefleur M. de Bruijn
WAWillem M. Ankum
Willem M. Ankum
JRJim A. Reekers
Jim A. Reekers
EBErwin Birnie
Erwin Birnie
SKSanne M. van der Kooij
Sanne M. van der Kooij
WHWouter J.K. Hehenkamp
Wouter J.K. Hehenkamp

1 December 2017 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
ABAnnefleur M. de Bruijn
Annefleur M. de Bruijn
MSMarieke Smink
Marieke Smink
PLPaul N.M. Lohle
Paul N.M. Lohle
JHJudith A.F. Huirne
Judith A.F. Huirne
JTJos W.R. Twisk
Jos W.R. Twisk
WHWouter J.K. Hehenkamp
Wouter J.K. Hehenkamp

17 May 2017 in CardioVascular and Interventional Radiology
Verified
Journal Article
Open access
PDF file
ABAnnefleur M. de Bruijn
Annefleur M. de Bruijn
MSMarieke Smink
Marieke Smink
WHWouter J. K. Hehenkamp
Wouter J. K. Hehenkamp
RNRobbert J. Nijenhuis
Robbert J. Nijenhuis
ASAlbert J. Smeets
Albert J. Smeets
PLPaul N. M. Lohle
Paul N. M. Lohle
Purpose The purpose of this study was to assess clinical outcomes 7 years after uterine artery embolization (UAE) in the treatment of symptomatic adenomyosis. Materials and Methods In this prospective cohort study, one specialized hospital in the Netherlands recruited patients with symptomatic adenomyosis or adenomyosis in combination with fibroids for UAE. The 7-year post-intervention outcomes were health-related quality of life (HRQOL), symptom severity scores (SSS), satisfaction, menopause and re-interventions. Results Twenty-nine patients with adenomyosis (15 with fibroids) were treated with UAE between September 2006 and January 2010. The 7-year questionnaire was mailed in November 2016. The mean follow-up was 95 months (SD 9.0) at a mean age of 50 (SD 5.4). Questionnaires were returned by 24/29 patients (83%). The remaining five patients were contacted through telephone. One of these patients was untraceable. Seven years after treatment 5 of 28 patients (18%) underwent a secondary hysterectomy. The HRQOL and SSS scores as measured by UFS-QOL at 3 months after UAE showed significant improvement of −57 points (score: 15) and +40 points (score: 91), respectively. These scores remained comparable stable up unto 7 years. The SSS showed a significant difference of 17 points (0–100) in favor of the adenomyosis in combination with fibroids group (p = 0.020). Menopause was reported by 10/28 patients (36%). Twenty-one of 29 (72%) patients declared to be at least fairly satisfied about UAE. Conclusions After 7 years of follow-up, in 82% of UAE-treated patients with symptomatic adenomyosis a hysterectomy was avoided.

1 March 2018 in JMIR Research Protocols
Verified
Journal Article
Open access
ABAnnefleur Machteld de Bruijn
Annefleur Machteld de Bruijn
PLPaul Nm Lohle
Paul Nm Lohle
JHJudith A.F. Huirne
Judith A.F. Huirne
JVJolanda de Vries
Jolanda de Vries
MTMoniek Twisk
Moniek Twisk
WHWouter Jk Hehenkamp
Wouter Jk Hehenkamp
Adenomyosis is a benign uterine disease characterized by invasion of endometrium into the myometrium resulting in heavy menstrual bleeding and pain (dysmenorrhea). Hysterectomy is established as the final treatment option when conservative treatment fails. Uterine artery embolization (UAE) in patients with symptomatic adenomyosis has demonstrated to reduce symptoms and improve quality of life. However, randomized controlled trials are lacking. With this study, we aim to evaluate the impact of UAE on Health-Related Quality of Life (HRQOL) in a randomized comparison to hysterectomy in patients with symptomatic adenomyosis. This is a multicenter non-blinded randomized controlled trial comparing UAE and hysterectomy. Eligible patients are symptomatic premenopausal women without the desire to conceive and who have symptomatic magnetic resonance imaging (MRI)-confirmed pure adenomyosis or dominant adenomyosis accompanied by fibroids. After obtaining informed consent, patients will be randomly allocated to treatment in a 2:1 UAE versus hysterectomy ratio. The primary objective is HRQOL at 6 months following the assigned intervention. Secondary outcomes are technical results, pain management, clinical outcomes, HRQOL, and cost effectiveness during 2 years of follow-up. In addition, transvaginal ultrasound (TVUS) and MRI will be performed at regular intervals after UAE. Patient enrollment started November 2015. The follow-up period will be completed two years after inclusion of the last patient. At the time of submission of this article, data cleaning and analyses have not yet started. This trial will provide insight for caretakers and future patients about the effect of UAE compared to the gold standard hysterectomy in the treatment of symptomatic adenomyosis and is therefore expected to improve patients' wellbeing and quality of life. Netherlands Trial Register NTR5615; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5615 (Archived by WebCite at http://www.webcitation.org/6xZRyXeIF).

4 October 2018 in CardioVascular and Interventional Radiology
Verified
Journal Article
Open access
PDF file
ABAnnefleur M. de Bruijn
Annefleur M. de Bruijn
SASven-Ole J. H. Adriaansens
Sven-Ole J. H. Adriaansens
MSMarieke Smink
Marieke Smink
AVAlexander Venmans
Alexander Venmans
WHWouter J. K. Hehenkamp
Wouter J. K. Hehenkamp
PLPaul N. M. Lohle
Paul N. M. Lohle
Purpose To perform an evaluation on safety and efficacy of uterine artery embolization (UAE) in the patients with symptomatic cervical leiomyomata. Methods Patients with symptomatic cervical leiomyomata who underwent UAE in one specialized hospital were retrospectively analyzed, both clinically and with MR imaging. The 3-month outcomes were assessed with MR imaging and a validated questionnaire. Long-term follow-up was assessed by direct contact or file review. To determine the efficacy of UAE for cervical leiomyomata, the primary objective was to assess the clinical outcome with the UFS-QOL questionnaire, containing the health-related quality of life (HRQOL) and symptom severity score (SSS). To assess safety, the secondary objective included leiomyomata volume reduction, the infarction/complication rate and secondary interventions were needed. Results Between 2006 and 2017, eight of 1180 patients underwent UAE and were eligible for inclusion. All embolizations were technically successful (n = 8). At 3 months, all patients showed cervical leiomyomata volume reduction with a median reduction of 41.5% (38.8 cm3) compared to baseline (p = 0.012). No complications occurred. At a median follow-up of 3 months (range 1–7, n = 7), the HRQOL and SSS improved with a median difference of 13 points (range − 5 to 60, p = 0.063) and − 13 points (range − 79 to 3, p = 0.046), respectively. Long-term follow-up showed two secondary interventions (median of 43.5 months). Six patients reported no symptom recurrence. Conclusion UAE in women with symptomatic cervical leiomyomata is effective and safe with significant improvement in symptoms and quality of life. UAE is a valuable option for women seeking a non-surgical solution.